RESPECT

BIONDI-SANTI LAUNCHES BRUNELLO DI MONTALCINO 2018

Retrieved on: 
Friday, March 1, 2024
Estate, Wine, Human voice, Ageing, Reserve wine, RESPECT, Season, History, La Voce, Brunello di Montalcino, QR, HERE, Wind, Viticulture

NEW YORK, March 1, 2024 /PRNewswire/ -- Biondi-Santi, the legendary Brunello di Montalcino producer, is pleased to announce the release of the 2018 vintage of Brunello di Montalcino.

Key Points: 
  • NEW YORK, March 1, 2024 /PRNewswire/ -- Biondi-Santi, the legendary Brunello di Montalcino producer, is pleased to announce the release of the 2018 vintage of Brunello di Montalcino.
  • The La Voce di Biondi-Santi audio experience will accompany each bottle of Brunello di Montalcino 2018, and wine lovers can access the listening experience by scanning the QR code on the proof tag on the capsule of the bottles.
  • 'La Voce di Biondi-Santi' is something we very much enjoy sharing with our customers and collectors, and we're excited to include it as part of our formal presentation of the 2018 Brunello this spring."
  • Commenting on the growing seasons for the 2018 Brunello di Montalcino, Federico Radi, Director of Viticulture and Winemaking, shares:
    "2018 was quite a cool year, characterized by abundant rainfalls which accompanied the entire growth cycle of the vine.

GordonMD® Announces Second Investment in Radiopharmaceutical Biotech Radionetics Oncology

Retrieved on: 
Friday, January 5, 2024
Radiology, Biotechnology, Pharmaceutical, Finance, Oncology, Health, Professional Services, Clinical Trials, NOT, ANY, MD, Investment, Growth, RESPECT

GordonMD® Global Investments LP, a key investor in groundbreaking healthcare solutions, announced another strategic investment in Radionetics Oncology.

Key Points: 
  • GordonMD® Global Investments LP, a key investor in groundbreaking healthcare solutions, announced another strategic investment in Radionetics Oncology.
  • Radionetics Oncology , a clinical stage radiopharmaceutical company, successfully secured a $52.5 million Series A financing round, led by Frazier Life Sciences, 5AM Ventures, and DCVC Bio, along with participation from GordonMD® and Crinetics Pharmaceuticals, bringing its total raised capital to $82.5 million.
  • “I believe Radionetics Oncology is poised to revolutionize cancer treatment with its pioneering radiopharmaceutical pipeline.
  • The firm focuses on identifying differentiated investment opportunities in biopharmaceutical companies primarily located in the U.S., Europe and Japan.

GordonMD® Announces Investment in Radiopharmaceutical Biotech Radionetics Oncology

Retrieved on: 
Tuesday, October 17, 2023
Research, Finance, Clinical Trials, Professional Services, Biotechnology, Radiology, Pharmaceutical, Health, Science, Oncology, Cancer, Lung cancer, Investment, Breast cancer, MD, Radionuclide, Therapy, Radiopharmaceutical, NOT, RESPECT, ANY, Neoplasm, Adrenocortical carcinoma, Venture, Pharmaceutical industry

Craig Gordon, MD, Chief Executive Officer of GordonMD® Global Investments LP, announced today that his firm has jointly invested in a private placement financing for Radionetics Oncology.

Key Points: 
  • Craig Gordon, MD, Chief Executive Officer of GordonMD® Global Investments LP, announced today that his firm has jointly invested in a private placement financing for Radionetics Oncology.
  • Radionetics Oncology, a clinical stage pharmaceutical company spun out of Crinetics (Nasdaq: CRNX) in 2021, focuses on the discovery and development of novel radiotherapeutics for the treatment of a wide range of oncology indications.
  • GordonMD® joins Frazier Healthcare, 5AM Ventures, and Crinetics Pharmaceuticals as investors in Radionetics.
  • “I believe Radionetics Oncology presents a unique investment opportunity.

Scilex Holding Company Provides Notice to All Record Holders and Beneficial Owners of Restricted Shares of Scilex Holding Company

Retrieved on: 
Tuesday, October 3, 2023
Transfer, ACT, ENTRY, Proposal, AS, Chapter 11, Title 11, United States Code, Official Committee of Equity Security Holders, CASH, Equity, Continental, CALL, United States bankruptcy court, OF, WITH, PUT, Bankruptcy, PALO, RESPECT, OR, NET, SMA, SELL, SALE, BY, DEADLINE, Documentation, ANY, OTC, COMMON, Chronic pain, Security (finance), Real estate, Debtor, Short, Lock up

The Scilex Dividend Stock was primarily received by “record holders,” or brokers, dealers, banks and other nominees acting as agents for shareholders who are the true “beneficial owners” of the Scilex Dividend Stock.

Key Points: 
  • The Scilex Dividend Stock was primarily received by “record holders,” or brokers, dealers, banks and other nominees acting as agents for shareholders who are the true “beneficial owners” of the Scilex Dividend Stock.
  • “Naked short” sales or “naked short” positions in any Scilex common stock may constitute a violation of SEC Regulation SHO.
  • If a holder of a short-position already holds unrestricted shares of Scilex common stock, such holder may convert such shares into restricted shares subject to the Lockup via the same process outlined herein.
  • b. Scilex and the buyer will jointly instruct Continental Stock Transfer & Trust Company, Scilex’s transfer agent (“Continental”), to impose the Lockup on the shares.

How long will a loved one live? It’s difficult to hear, but harder not to know

Retrieved on: 
Monday, September 25, 2023
Life, RESPECT, Survival, Quality of life, Terminal, Statistics, Dignity, Research, Goal, Life expectancy, Translation, Nursing, Intention, Retirement, Patient, Cooking, Frailty, Learning, Algorithm, Community Tool Box, Palliative care, Project, Risk, Mathematics, Health, Death, Residential care, Pharmaceutical industry, Medical device, Transport

Clinicians, based on their experience, can offer broad estimates of survival — in days to weeks, weeks to months, or months to years.

Key Points: 
  • Clinicians, based on their experience, can offer broad estimates of survival — in days to weeks, weeks to months, or months to years.
  • However, patients and their care partners often want greater precision when arranging or making decisions about their care.
  • However, even for an experienced clinician, estimating the life expectancy of a patient with a serious illness is challenging.

A tool for timely conversations and planning

    • RESPECT (Risk Evaluation for Support: Predictions for Elder life in their Communities Tool) is a risk communication tool powered by prediction algorithms that estimate individuals’ survival — that is, how long someone will live.
    • RESPECT was designed with patients’ information needs in mind, and with the intention of empowering patients and their care partners.

A tool for patients, care partners and clinicians

    • Older adults, their care partners and health care professionals who are uncertain about the life expectancy of someone living with a critical illness can use the calculator to gain a better understanding of their decline.
    • A patient can use this information to discuss their care needs with their care partners and health-care providers.
    • Earlier conversations about the older person’s goals and wishes for their remaining life can enable the care team to provide the best quality of life and care for the individuals under their care.

Sustainable infrastructure

    • One of the goals of RESPECT is to provide sustainable infrastructure to study, learn and improve how we use predictive algorithms for end-of-life care.
    • Despite the benefits that are emerging from the early uses of RESPECT, many questions remain about when and how it can be most appropriately used.

Identification is just the first step

    • Lysanne Lessard receives funding from Canadian Institutes of Health Research for research related to the RESPECT Learning Health System.
    • Amy T. Hsu receives funding from the Canadian Institutes of Health Research for research related to the RESPECT Calculator.
    • Peter Tanuseputro receives funding from the Canadian Institutes of Health Research for research related to the RESPECT calculator.

AI is quietly building financial intelligence for younger Canadians, yet skepticism remains, reveals new RBC Survey

Retrieved on: 
Monday, August 28, 2023
Tilton, RBC, GPS, Ipsos, Personal, RESPECT, Perception, Save, Customer experience, Commercial bank, Machine learning, Artificial intelligence, Ageing, AI, Digital, Sales, Dairy, Medical device, Customer service

From automated savings and budgeting to quick insights and cash flow forecasting, AI quietly yet significantly changes how Canadians can handle their finances.

Key Points: 
  • From automated savings and budgeting to quick insights and cash flow forecasting, AI quietly yet significantly changes how Canadians can handle their finances.
  • "We believe AI is revolutionizing personal finance management," says Peter Tilton, chief digital officer, Personal & Commercial Banking at RBC.
  • "The ability to harness the power of AI can help level the playing field in terms of financial literacy for Canadians.
  • With RBC's renowned digital team and Borealis AI, an RBC-backed AI research center, RBC continues to innovate and explore the development of responsible AI.

GordonMD® Invests in Private Placement for Taysha Gene Therapies

Retrieved on: 
Monday, August 21, 2023
Biotechnology, Health, Genetics, Pharmaceutical, Clinical Trials, NOT, Central nervous system, Civil service commission, Investment, RESPECT, Rett syndrome, MECP2, AAV, CNS, Giant axonal neuropathy, Orphan drug, GAN, MD, Risk, ANY, Rare, FDA, Notre Dame Institute for Global Investing, European Commission, Pharmaceutical industry

GordonMD® Global Investments LP announced today it has participated in a $150 million private placement financing for Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a clinical-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system (CNS).

Key Points: 
  • GordonMD® Global Investments LP announced today it has participated in a $150 million private placement financing for Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a clinical-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system (CNS).
  • Rett syndrome is a rare genetic neurodevelopmental disorder caused by mutations in the X-linked MECP2 gene.
  • TSHA-102 utilizes a novel miRARE platform designed to mediate levels of MECP2 in the CNS on a cell-by-cell basis without risk of overexpression.
  • The firm manages a private fund and a public fund, each focused on differentiated investment opportunities in biopharmaceutical companies primarily located in the U.S., Europe and Japan.

THE BARBARA SINATRA CHILDREN'S CENTER TO DEBUT SHORT FILM "ARE YOU LISTENING?" TO RAISE AWARENESS FOR YOUTH-ON-YOUTH CONSENT

Retrieved on: 
Monday, August 21, 2023
Parent, RESPECT, Are You Listening, Army Heritage Center Foundation, Friends, Safety, Anybody's Nightmare, Toy

RANCHO MIRAGE, Calif., Aug. 21, 2023 /PRNewswire/ -- The Barbara Sinatra Children's Center Foundation released today a short film titled, Are You Listening? in collaboration with Wonder Media. This video was created as a part of The Barbara Sinatra Children's Center's FightChildAbuse.org Teen Series, focusing on the importance of youth-on-youth consent. According to the Center, youth who experience sexual assault are more likely to be victimized by a peer or a partner, and of the 1 in 4 girls who suffer some type of sexual assault by age 18, nearly 30% are victimized by a current partner.

Key Points: 
  • This short film was created with Wonder Media and will be a free, online resource available to teens, educators and parents
    RANCHO MIRAGE, Calif., Aug. 21, 2023 /PRNewswire/ -- The Barbara Sinatra Children's Center Foundation released today a short film titled, Are You Listening?
  • This video was created as a part of The Barbara Sinatra Children's Center's FightChildAbuse.org Teen Series, focusing on the importance of youth-on-youth consent.
  • This discovery helps Ivy, Taryn and Kai remember the importance of "ASK, LISTEN, RESPECT" in order to keep each other safe.
  • The film follows the Barbara Sinatra Children's Center Foundation's award-winning 2021 short film release, Are You Okay?

GordonMD® Invests in Clinical Stage Cell Therapy Company Kyverna

Retrieved on: 
Tuesday, August 15, 2023
Biotechnology, Pharmaceutical, Finance, Health, Banking, Professional Services, Genetics, Clinical Trials, Gilead Sciences, NOT, CD19, Investment, RESPECT, Cancer, CAR, MD, Patient, Engineering, Capital, RTW, Lupus nephritis, ANY, Notre Dame Institute for Global Investing, Insight Partners, Pharmaceutical industry

GordonMD® Global Investments LP participated in a $60 million Series B financing round extension for Kyverna Therapeutics, a clinical-stage cell therapy company with the mission of engineering a new class of therapies for autoimmune diseases.

Key Points: 
  • GordonMD® Global Investments LP participated in a $60 million Series B financing round extension for Kyverna Therapeutics, a clinical-stage cell therapy company with the mission of engineering a new class of therapies for autoimmune diseases.
  • "We are pleased by the increasing investor confidence in the promise of Kyverna's anti-CD19 CAR T-cell therapy for autoimmune diseases," said Ryan Jones, chief financial officer of Kyverna.
  • Craig Gordon, M.D., founder, chief executive officer, and chief investment officer of Gordon MD® Global Investments said: "I have supported anti-CD19 CAR T-cell therapy for cancer since the early clinical trials.
  • It is exciting to see Kyverna break into new frontiers by advancing cell therapies for autoimmune diseases.

MSCI Equity Indexes August 2023 Index Review

Retrieved on: 
Thursday, August 10, 2023
Professional Services, Business, Other Professional Services, Finance, Consulting, Banking, Global Industry Classification Standard, GCC, Marketing, IMI, GICS, RESULTS, GFH, Dish Network, Risk, ESG, WITH, EACH, NYSE, Personal injury, Software, Real, Fox Broadcasting Co. v. Dish Network, LLC, IPD, RESPECT, Privacy, Gongniu, AND, Research, S&P Global, Name, Death, Human, ETF, Investment Advisers Act of 1940, RiskMetrics, CNPC, Judgement, Information, USE, BSC, Palo Alto Networks, Real estate, ADV, Person, EXPRESS, ANY, GFH Financial Group, Cryptocurrency, Birth control, Life insurance, Risk management, Security (finance), Financial adviser, Index, MSCI, GIF, Vif

MSCI Inc. (NYSE:MSCI), a leading provider of critical decision support tools and services for the global investment community, announced the results of the August 2023 Index Review for the MSCI Equity Indexes - including the MSCI Global Standard, MSCI Global Small Cap and MSCI Micro Cap Indexes, the MSCI Frontier Markets, and MSCI Frontier Markets Small Cap Indexes, the MSCI Global Islamic and MSCI Global Islamic Small Cap Indexes, the MSCI US Equity Indexes, the MSCI US REIT Index, the MSCI China A Onshore indexes and the MSCI China All Shares Indexes.

Key Points: 
  • MSCI Inc. (NYSE:MSCI), a leading provider of critical decision support tools and services for the global investment community, announced the results of the August 2023 Index Review for the MSCI Equity Indexes - including the MSCI Global Standard, MSCI Global Small Cap and MSCI Micro Cap Indexes, the MSCI Frontier Markets, and MSCI Frontier Markets Small Cap Indexes, the MSCI Global Islamic and MSCI Global Islamic Small Cap Indexes, the MSCI US Equity Indexes, the MSCI US REIT Index, the MSCI China A Onshore indexes and the MSCI China All Shares Indexes.
  • MSCI US Equity Indexes: There will be no securities added to and no securities deleted from the MSCI US Large Cap 300 Index.
  • Accordingly, constituents in MSCI equity indexes may include MSCI Inc., clients of MSCI or suppliers to MSCI.
  • MSCI ESG and climate ratings, research and data are produced by MSCI ESG Research LLC, a subsidiary of MSCI Inc. MSCI ESG Indexes, Analytics and Real Estate are products of MSCI Inc. that utilize information from MSCI ESG Research LLC.